REMARKS

In response to the restriction requirement dated August 18, 2006, Applicants elect claims related to Group I claims directed to the augmentation of activin signaling. Please cancel claims 1, 4-12, and 15-33 and add new claims 34-37 directed to the augmentation of activin signaling by contacting a cell with an anti-betaglycan antibody. No new matter has been added and support for the new claims can be found in example 9, the claims as originally filed, and the summary of invention section of the specification.

The Examiner is invited to contact the undersigned agent at (512) 536-3167 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

Charles P. Landrum Reg. No. 46,855

Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201 (512) 536-4598 (facsimile)

Date:

October 18, 2006